Charles C. Wykoff, MD, PhD
Show Description +
Charles C. Wykoff, MD, PhD, speaks about KSI-301, a novel antibody biopolymer conjugate (ABC) designed to block VEGF-A isoforms. Dr. Wykoff details the design and results of a phase 1b study that assessed KSI-301 in patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
Posted: 9/11/2019
Charles C. Wykoff, MD, PhD
Charles C. Wykoff, MD, PhD, speaks about KSI-301, a novel antibody biopolymer conjugate (ABC) designed to block VEGF-A isoforms. Dr. Wykoff details the design and results of a phase 1b study that assessed KSI-301 in patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
Posted: 9/11/2019
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2019.
Please log in to leave a comment.